Response to Regulatory Questions (RTQ)
0.1.0 - ci-build

Response to Regulatory Questions (RTQ), published by HL7 International. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/rtq-ig/ and changes regularly. See the Directory of published versions

: RegulatoryQA-ID001-Response - TTL Representation

Raw ttl | Download


@prefix fhir: <http://hl7.org/fhir/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

# - resource -------------------------------------------------------------------

 a fhir:QuestionnaireResponse ;
  fhir:nodeRole fhir:treeRoot ;
  fhir:id [ fhir:v "RegulatoryQA-ID001-Response"] ; # 
  fhir:meta [
fhir:versionId [ fhir:v "1" ] ;
fhir:lastUpdated [ fhir:v "2025-11-15T14:59:00-05:00"^^xsd:dateTime ] ;
    ( fhir:profile [
fhir:v "http://hl7.org/fhir/uv/brr/StructureDefinition/RegulatoryQuestionnaireResponse"^^xsd:anyURI ;
fhir:l <http://hl7.org/fhir/uv/brr/StructureDefinition/RegulatoryQuestionnaireResponse>     ] )
  ] ; # 
  fhir:text [
fhir:status [ fhir:v "generated" ] ;
fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n      <h2>Response to Regulatory Questionnaire ID001</h2>\n      <p><b>Procedure:</b> EMEA/H/C/005432/II/0023</p>\n      <p><b>Product:</b> ExampleDrug 10 mg Tablets</p>\n      <p><b>Submitted by:</b> SynthPharma AG</p>\n      <p><b>Submitted to:</b> European Medicines Agency (EMA)</p>\n      <p><b>Date:</b> November 15, 2025</p>\n      <hr/>\n      <p>This response addresses all administrative, labeling, and CMC stability questions for the Type II Variation.</p>\n    </div>"^^rdf:XMLLiteral ]
  ] ; #  Narrative 
  fhir:identifier ( [
fhir:system [
fhir:v "http://hl7.org/fhir/uv/brr/identifier/qa-request"^^xsd:anyURI ;
fhir:l <http://hl7.org/fhir/uv/brr/identifier/qa-request>     ] ;
fhir:value [ fhir:v "ID001" ]
  ] [
fhir:system [
fhir:v "https://ema.europa.eu/procedure-number"^^xsd:anyURI ;
fhir:l <https://ema.europa.eu/procedure-number>     ] ;
fhir:value [ fhir:v "EMEA/H/C/005432/II/0023" ]
  ] ) ; #  Identifiers 
  fhir:questionnaire [
fhir:v "http://hl7.org/fhir/uv/brr/Questionnaire/brr-regulatory-qa-questionnaire"^^xsd:anyURI ;
fhir:l <http://hl7.org/fhir/uv/brr/Questionnaire/brr-regulatory-qa-questionnaire>
  ] ; #  Reference to original Questionnaire 
  fhir:status [ fhir:v "completed"] ; # 
  fhir:subject [
fhir:l fhir:MedicinalProductDefinition/example-drug-10mg ;
fhir:reference [ fhir:v "MedicinalProductDefinition/example-drug-10mg" ] ;
fhir:display [ fhir:v "ExampleDrug 10 mg Tablets" ]
  ] ; # 
  fhir:authored [ fhir:v "2025-11-15T14:59:00-05:00"^^xsd:dateTime] ; # 
  fhir:item ( [
fhir:linkId [ fhir:v "admin-1" ] ;
fhir:text [ fhir:v "Is the fee for the Type II variation fully paid and documented?" ] ;
    ( fhir:answer [
fhir:value [
a fhir:String ;
fhir:v "Yes, the fee was paid on June 25, 2025. Payment confirmation and receipt are included in the application form (see Section 1.1)."       ]     ] )
  ] [
fhir:linkId [ fhir:v "admin-2" ] ;
fhir:text [ fhir:v "Are all required metadata fields in the application form complete?" ] ;
    ( fhir:answer [
fhir:value [
a fhir:String ;
fhir:v "Yes, all required metadata fields are complete: • MAH: SynthPharma AG • Product: ExampleDrug 10 mg Tablets • Procedure: EMEA/H/C/005432/II/0023 • Submission Date: 2025-06-25"       ]     ] )
  ] [
fhir:linkId [ fhir:v "labeling-1" ] ;
fhir:text [ fhir:v "Do the updated storage conditions (2–8°C for 36 months) require additional patient guidance?" ] ;
    ( fhir:answer [
fhir:value [
a fhir:String ;
fhir:v "No additional patient guidance is required. The ePI clearly states: 'Store in a refrigerator (2°C – 8°C). Do not freeze.' The 36-month shelf life is supported by stability data and does not alter patient handling instructions."       ]     ] )
  ] [
fhir:linkId [ fhir:v "labeling-2" ] ;
fhir:text [ fhir:v "Is the patient leaflet revised to clarify the extended shelf life?" ] ;
    ( fhir:answer [
fhir:value [
a fhir:String ;
fhir:v "Yes, the patient leaflet has been updated to state: 'Shelf life after first opening: 36 months when stored at 2–8°C'. The revised leaflet is included in the submission."       ]     ] )
  ] [
fhir:linkId [ fhir:v "labeling-3" ] ;
fhir:text [ fhir:v "Is the updated ePI text sufficiently clear for all EU languages?" ] ;
    ( fhir:answer [
fhir:value [
a fhir:String ;
fhir:v "Yes, the ePI text has been translated into all EU languages and reviewed for clarity. All versions are linguistically validated. Status: English (Approved), French (Approved), German (Approved), others (Final review completed)."       ]     ] )
  ] [
fhir:linkId [ fhir:v "cmc-1-DP-Stability" ] ;
fhir:text [ fhir:v "Are there any new stability studies conducted, or does the submission include only data from additional timepoints from previously submitted studies?" ] ;
    ( fhir:answer [
fhir:value [
a fhir:String ;
fhir:v "The submission includes both: • Additional timepoints: Long-term data extended to 36 months for primary batches A-001, A-002, A-003. • New stability studies: Two pilot-scale batches (B-001, B-002) in new Alu/Alu packaging, with 6-month accelerated (40°C/75% RH) and long-term (25°C/60% RH) data. No protocol deviations occurred. All studies follow ICH Q1A(R2)."       ]     ] )
  ] [
fhir:linkId [ fhir:v "cmc-2-DP-Stability" ] ;
fhir:text [ fhir:v "Does the data support all intended climatic zones?" ] ;
    ( fhir:answer [
fhir:value [
a fhir:String ;
fhir:v "Yes, the data supports all ICH climatic zones, including Zone IVb: • Zone I/II: 25°C/60% RH (long-term), 40°C/75% RH (accelerated) • Zone IVb: 30°C/75% RH (long-term) — data confirms compliance per WHO TRS 1010. All batches remain within specification."       ]     ] )
  ] [
fhir:linkId [ fhir:v "cmc-3-DP-Analytical Methods" ] ;
fhir:text [ fhir:v "Are the test methods used the same as in the previously submitted stability information?" ] ;
    ( fhir:answer [
fhir:value [
a fhir:String ;
fhir:v "Yes, all test methods are identical to those validated in the original MAA. No changes were made. Methods remain stability-indicating for assay, impurities, and dissolution."       ]     ] )
  ] [
fhir:linkId [ fhir:v "cmc-4-DP-Impurities" ] ;
fhir:text [ fhir:v "Are there any new degradation products identified within the newly submitted data?" ] ;
    ( fhir:answer [
fhir:value [
a fhir:String ;
fhir:v "No new degradation products were identified. All observed impurities correspond to previously qualified degradants. Levels remain below 0.10% (ICH Q3B(R2) threshold). No peaks above reporting threshold detected."       ]     ] )
  ] [
fhir:linkId [ fhir:v "cmc-5-DP-Container Closure System" ] ;
fhir:text [ fhir:v "Any changes in the packaging configuration and/or storage of the samples during stability?" ] ;
    ( fhir:answer [
      ( fhir:extension [
fhir:url [
fhir:v "http://hl7.org/fhir/uv/brr/StructureDefinition/questionnaire-itemRichText"^^xsd:anyURI ;
fhir:l <http://hl7.org/fhir/uv/brr/StructureDefinition/questionnaire-itemRichText>         ] ;
fhir:value [ a fhir:Xhtml ]       ] ) ;
fhir:value [
a fhir:String ;
fhir:v "Yes, packaging changed from PVC/PVDC to Alu/Alu. New stability studies initiated. See rich text for diagram and details."       ]     ] )
  ] ) . #  ====================== ANSWERS (exact match with Questionnaire) ====================== ,  admin-1